Because lung function can be substantially reduced by the time most chronic obstructive pulmonary disease (COPD) patients first see a physician, maintenance treatment should be considered at the time of diagnosis, according to new data analyses presented at the American Thoracic Society (ATS) 2015 International Conference.
The Centers for Medicare and Medicaid Services recently instituted a billing code that finally reimburses providers separately for non-face-to-face services.
Rather than reducing unnecessary, preventable emergency department visits, some healthcare experts say the Affordable Care Act has actually caused them to increase.
Insurers have raised concerns about the regulation and approval process of medical devices in the wake of a recent advisory notice issued by the FDA on the risks of laparoscopic power morcellators.
More than 750 government and private ACOs are now in place, helping healthcare transition away from fee-for-service. Find out what's working and what's planned for the future.
As the number of people with diabetes in the U.S. continues to climb, plans and integrated health systems are employing personalized strategies to help manage the disease.
Critics charge that the practice of adverse tiering to deter costly patients is violating the Affordable Care Act's coverage mandate.
In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), investigational indacaterol/glycopyrronium (QVA149) bromide significantly improved lung function compared to the single bronchodilators, according to data presented at the American Thoracic Society (ATS) International Conference in Denver, May 15 to 20.
The Centers for Medicare & Medicaid Services (CMS) proposed to modernize Medicaid and Children’s Health Insurance Program (CHIP) managed care regulations to update the programs’ rules and strengthen the delivery of quality care for beneficiaries. This proposed rule is the first major update to Medicaid and CHIP managed care regulations in more than 10 years.
FDA has joined nonprofit National Forum for Heart Disease and Stroke Prevention to advance the cause of a heart-healthy and stroke-free society in a first-of-its-kind cooperative public education program to reduce the burdens of heart disease and stroke.
Because of overuse and misuse, some antibiotics are losing effectiveness against highly resistant bacteria.
The FDA approved Eli Lilly’s Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), the company announced on May 27.
Among the many poster sessions being presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, are several on the latest trials that are planned to evaluate potential treatment options for breast cancer. These trials include 1 phase 2 study and 3 phase 3 studies.
The FDA approved two new treatments to treat irritable bowel syndrome with diarrhea (IBS-D), Viberzi (eluxadoline) and Xifaxan (rifaximin), this week.
A new survey indicates consumers' biggest concerns about health insurance marketplace plans, and the top factors they consider when selecting a plan.
If we can accurately understand each patient’s risk for disease, we can create more nuanced preventive care plans and better invest our resources.
To survive, hospital executives must find new and creative ways to help uninsured and low-income patients secure health insurance.
FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
A significant spike in prescription drug costs helped drive healthcare costs for families covered under an average employer's health insurance plan up an estimated 6.3% in 2015, according to the Milliman Medical Index (MMI) report.
CVS Health’s acquisition of Omnicare for $12.7 billion is expected to significantly expand the drug chain’s business in specialty pharmacy, generics and long-term care.
This summer, Amgen and Regeneron Pharmaceuticals/ Sanofi will battle it out in the competitive cholesterol market. Repatha and Praluent, respectively, are expected to be approved by the FDA this summer.
The higher cure rate of treating hepatitis C patients with a combination of ledipasvir and sofosbuvir (Harvoni) led to substantially better work productivity, according to a new study. In fact, improved work productivity and lack of absenteeism could save the United States and 5 European countries more than $3.2 billion a year.
By working with service providers that are employing robotics and advanced analytics, organizations can leverage automation and innovation to address key challenges.
In this blog, the vice president of medical affairs for Quest Diagnostics discusses how Medicaid expansion has impacted diabetes diagnoses.
Johnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs.
In FDA's 2012 Draft Guidance on Biosimilars, the Agency called for "labeling of a proposed product to include all the information necessary for a health professional to make prescribing decisions," including clear statements of a product's approval as a biosimilar to a reference product and whether or not it has been determined to be interchangeable.
Health exchange Covered California said it is the first in the United States to adopt benefit design changes to improve access to high-cost specialty drugs.
FDA has approved the first and only 4-times-per-year schizophrenia drug.
After more than 20 years with America's Health Insurance Plans (AHIP) as president and CEO, Karen Ignagni is leaving the organization to become the CEO of New York-based EmblemHealth.She will replace Frank Branchini effective September 1. Branchini, who has served EmblemHealth and its predecessor GHI as president/CEO for 30 years, will continue as the Chair of the Board of Directors.
